Brachytherapy (BRT) is used in the treatment of human cancers, including the cervix, breast, prostate and head and neck cancers. The primary advantage of BRT lies in the spatial conformation of the radiation deposition. Previously, we have shown that similar techniques (using hollow metallic cylinders) may be used to deliver gene-therapy vectors capable of expressing the radiationsensitizing cytokine, tumor necrosis factor (TNF)-a, within a restricted volume of tissue. Herein, we report radiation sensitization of cancer cells using a TNF-a expressing vector driven by the radiation-inducible immediate-early gene-1 (IEX-1) promoter (pIEX-TNFa). TNF-a, determined by ELISA assays using culture medium, increased between 5 and 10 fold, 48 h following exposure to radiation, and radiation sensitization was comparable with that observed in cells in which TNF-a was constitutively expressed under cytomegalo viral (CMV) promoter using the plasmid vector (pCMV-TNF-a). This efficiency of induced TNF-a radiation sensitization was also observed in cervix (SW756) and prostate tumor (PC-3) xenograft models. IEX-1-driven TNF-a expression following external radiation exposure resulted in enhanced regression of tumor xenografts as compared with radiation alone. A feasibility of using radioactive Pd-103 seeds with GeneSeeds was further examined using PC-3 xenograft models. The data showed substantial tumor growth suppression following co-implantation with a metal seed containing Pd-103. Taken together, these results show the enhanced effect on tumor regression by treatment with radiation-inducible TNF-a expression in combination with radiation and support for the IEX-1 promoter as a useful regulator for temporal activation of radiation-sensitizing gene expression.
Introduction
Radiation therapy is an established treatment modality for the management of clinically localized prostate cancer. The common methods for delivering radiation therapy include external beam treatment, brachytherapy (BRT) and combinations of the two. [1] [2] [3] The effectiveness of radiation therapy is well documented by comparisons with radical prostatectomy; 4 however, with the advent of the test for prostate-specific antigen, it has become evident that treatment failure may occur more frequently than previously appreciated following both radiation therapy and surgery. [5] [6] [7] [8] Furthermore, post-radiation therapy biopsies have revealed more locally persistent disease than expected and the local failures following radiation therapy eventually result in higher metastatic rates. 9, 10 Therefore, improved local control of prostate cancer predicts reduced local sequelae (uncontrolled pelvic disease) and improved survival (decreased metastatic disease).
BRT refers to direct placement of radioactive pellets or seeds at the site of disease. This modality has been extensively used for treating early stage prostate cancers. 2 Radioactive implants deliver a highly concentrated dose of radiation to the prostate. Transrectal ultrasound and computed tomography imaging modalities combined with computed tomography guided dosimetry and transperineal techniques, and allow accurate placement of radioactive seeds in the prostate gland. 3 Recent reports indicate that biochemical cures (outcome) can be achieved using this technique in early stage prostate cancer patients. 4 Implanted radioactive sources deliver highly localized radiation doses. [3] [4] [5] [6] [7] [8] [9] [10] [11] Owing to the favorable 'inverse square' distance effects from radiation sources, much of the bladder and rectum can be spared major damage with this technique. This commonly used procedure results in long-term control or 'cure' for many patients. However, the number of radioactive seeds implanted in the prostate can be large (4100). The larger the prostate is, the more radioactive seeds need to be placed and the more difficult to achieve optimal dose distribution. Therefore, improvements on the BRT concept are needed.
Radiation and gene therapy have previously been combined for the treatment of local disease, killing tumor cells via independent mechanisms, thereby reducing the emergence of cells resistant to one or the other treatments. With radiosensitization, enhanced local tumor control may be achieved in radioresistant tumors, and radiosensitive tumors may be controlled with lower doses of radiation, thereby potentially reducing radiation damage to normal tissue parenchyma surrounding the tumor. 12 Radiation sensitization of tumors has been a long-term goal of radiation oncologists and biologists. Delivery of genes or cytokines into a tumor offers a particularly attractive option. Cytokines, such as tumor necrosis factor (TNF), interleukins and interferons, are attractive agents for cancer therapy. Clinical trials of a combination of TNF-a and radiotherapy, using an external radiation sources, have produced encouraging preliminary results.
12-14 TNF-a, such as expressed by adenovirus, has shown anti-tumor action and synergism with radiation in cytotoxic effects. Such dual functions of TNFa in cell killing and radiosensitization offer a novel approach to improve the therapeutic window for treatment of patients. [15] [16] [17] However, administration of recombinant cytokines has proven toxic. Bolus cytokine delivery regionally has led to systemic toxicity, presumably through cytokine diffusion into the blood stream or dose dumping. Such barriers to the use of cytokines may be overcome by the use of plasmids encoding cytokines. Secretion of cytokines into the tumor environment by the fraction of cells taking up and expressing plasmid offers treatment over extended time periods.
Cellular exposure to ionizing radiation results in the transcriptional activation of so-called immediate-early genes. Some of these encode transcription factors, which increase expression of genes controlling cell cycle arrest, DNA damage repair, cellular survival and death. Of the several known radiation-responding genes, the radiationinducible immediate-early gene-1 (IEX-1) has been identified by our group. 18 IEX-1 has also been characterized as an anti-apoptotic factor. [19] [20] [21] The rapid expression of this gene after radiation provides an opportunity for developing radiation-inducible gene-therapy vectors; that is, the expression of coding sequence under the control of the IEX-1 promoter could be easily controlled during radiation therapy. In principle, gene expression from these vectors could be induced in specific but limited target regions by external ionizing radiation sources, especially induction by conformal radiotherapy. Appropriate manipulation of the IEX-1 promoter region may allow us to achieve extremely high intratumoral gene expression levels for a variety of anti-tumor agents.
Previously, we have reported a novel approach to deliver targeted genes to tumor by adapting prostate BRT technology to interstitial gene therapy using 'GeneSeed', which we have developed and manufactured. 22 The GeneSeeds are hollow metallic cylinders capable of holding and delivering precise volumes of solution containing vectors to tumor locations with millimeter precision. This technology offers improvements in the precision and uniformity of distribution of the vectors within the tumor volume is achievable. Here, we report a combinational approach with interstitial GeneSeeds technology and interstitial BRT for radiation sensitization in human cervix and prostate tumor xenografts.
Materials and methods
Cell lines and GeneSeeds PC3 and SW756 cells were obtained from the Cell Culture Core facility at the Lombardi Cancer Center, the Georgetown University Medical Center, and maintained in MEM containing 5% fetal calf serum at 37 1C in 5% CO 2 with penicillin and streptomycin added to all media, and routinely tested to ensure freedom from mycoplasma contamination. The prototype GeneSeed and radioactive seeds containing Pd-103 were manufactured for us by Best Industries (Springfield, VA). The titanium used was the same grade as has been in use for surgical implants for interstitial treatment of cancer. The seeds readily hold 1-2 ml of plasmid in lipofectin and are suitable for preclinical studies. 22 These seeds were designed to our specifications in collaboration with Best Industries, a manufacturer of radioactive seeds. 22 Cloning vector and in vitro TNF-a assay The plasmid vector, pIEX-1-TNF-a, was constructed by linking the 5 0 UTR (nt þ 1 toÀ1419) of IEX-1 gene to the human TNF-a cDNA (ATCC). The promoter of the IEX-1 gene was isolated from human placenta cDNA library with the PromoterFinder DNA walking kit (Clontech, Mountain View, CA) and primers (primer #1: 5 0 -AGTGCTGAGGTCCAGAGCGT, selected within the open reading frame and primer #2: 5 0 -GTCCCGGGAT GGTGGAGGGG, provided in the kit as a 'nested' adapter primer). The product was then sub-cloned into a eukaryotic expression vector (pCEP4-D promoter) (Invitrogen, Carlsbad, CA) and linked to human TNF-a fulllength cDNA isolated from HL-60 cells. Cells transfected with either 1 mg of pCMV-or pIEX-1-TNF-a using lipofectamine transfection kit (Invitrogen) were exposed to sham or 10 Gy of g-radiation using a Mark-30 irradiator with a 137 Cs source at a fixed dose rate of 2.71 Gy min -1 at indicated intervals. The amount of TNF-a in the cultured medium was then quantified by ELISA assays at the indicated times using a Quantikine TNF-a ELISA kit (R&D kit Systems, Minneapolis, MN). The amount of TNF-a in the medium of IEX-TNF-a after sham irradiation was used for normalization of subjects. The data were presented as means ± s.e.m.
Radiation clonogenic survival assay
Logarithmically growing PC3 cells transfected with vector only, pCMV-TNF-a or pIEX-TNF-a, were seeded and grown in T-25 flasks at various densities for 24 h. Cells were then exposed to two single doses, 5 and 10 Gy of g-radiation (a Mark-30 irradiator with a Subcutaneous tumor model and implantation of GeneSeeds Human cancer cell xenograft tumors were used in athymic male for PC3 and female for SW756 mice to study the efficiency of GeneSeeds (3-mm in length) to deliver plasmid vectors as described. 22 All animal procedures were approved by the Georgetown University Animal Care and Use Committee. A total of 5 Â 10 6 PC3 cells in 0.1 ml were subcutaneously injected. Tumors were measured by external caliper and volumes were calculated (length Â (width)
2 Â B/6). Mice were then implanted with GeneSeeds (filled with Lipfectin-control or plasmid DNA containing TNF-a) when the tumors measured B100 mm 3 . Ten animals were randomly assigned to the four treatment groups: lipofectin(control), pCMV-TNF-a, IR and pIEX-TNF-a þ IR.
Radiation treatment
For experiments using external radiation, the animals were irradiated with 2 Gy on days 1-5 and days 8-12 using a g-irradiator (Mark-30 irradiator). Animals were shielded with lead so that only the tumor was irradiated. Non-irradiated tumors serve as controls. For experiments, radioactive sources, Pd-103 seeds (100 mCi per seed), were implanted proximate to the tumor using hollow stainless steel needle applicator (Best Medical, Springfield, VA). Tumor dimensions were measured weekly for 75 days. The tumor volumes were measured twice per week. When the tumor volume was 41200 mm 3 , the mice were killed according to the animal protocol.
Statistical analysis
The tumor volume was calculated as the percentage of pre-treatment tumor volume and the mean percent tumor volume±s.e. was plotted. All statistical analysis was performed on the relative tumor volume (initial tumor volume ¼ V o ¼ 1) rather than the actual tumor volume to remove variations caused by differences in initial tumor size. Student's t-tests were performed to determine whether the relative volume differences between the treatments were significantly different throughout the duration of the time course was significant. Analysis of variance (one-way ANOVA) was performed to determine the statistical significance of changes in tumor volumes. For multiple comparisons, Duncan's multiple range test was used. Po0.05 is considered statistically significant.
Results

Expression of TNF-a in cultured prostate cancer cells (PC3)
Before applying our radiation-inducible expression vector system in vivo, we compared the efficacy of radiation-induced expression with expression driven by a cytomegalo viral (CMV) promoter in cultured prostate cancer cells. PC3 cells were transfected with plasmid vectors expressing TNF-a under the control of the CMV promoter (pCMV-TNF-a) or the entire promoter of the immediate-early radiation response gene IEX-1 (pIEX-1-TNF-a). The amounts of TNF-a released into the culture medium were measured using an ELISA assay system (Figure 1) . The level of TNF-a, 24 h following pCMV-TNF-a transfection, was 9.08 pg ml -1 and increased to 19.92 pg ml -1 by 48 h. Whereas, the level of TNF-a driven by the IEX-1 promoter was much less (2 pg ml -1 ), similar to mock-transfected controls (2.4 pg ml -1 ). However, the level of secreted TNF-a using the IEX-1 promoter-driven vector was significantly increased to 30.41 pg ml -1 72 h following radiation exposure. Radiation treatment confers no additional effect on the secretion of TNF-a produced by the pCMV-TNF-a vector (data not shown). Similar results were obtained in SW756 cell (data not shown). These data show that both vectors tested can secrete significant amounts of target protein under appropriate conditions, supporting the feasibility of using these vectors for further studies.
Next, the effect of TNF-a expression on cellular radiation sensitivity was determined in transfected cells exposed to either 5 or 10 Gy (Figure 2 ). Cells transfected with either pCMV-TNF-a or pIEX-1-TNF-a were markedly sensitized to radiation as compared with control cells transfected with vector only, suggesting that constitutively expressed TNF-a is sufficient to kill cells.
Taken together, the experimental results show that cellular radiation sensitivity is increased by TNF-a expression from either constitutively expressed by the CMV promoter or only after radiation for the IEX Figure 1 Quantification of TNF-a. Following transfection of PC3 cells with TNF-a expression vectors, accumulation of TNF-a in the cultured medium was quantified by ELISA assays at the indicated times after transfection. Cells transfected with either pCMV-or pIEX-1-TNF-a were exposed to 10 Gy of g-radiation at the times (after transfection) indicated and the amounts of TNF-a protein released into the medium was measured 1 h later. The levels of TNF-a in irradiated samples were normalized to levels in sham-irradiated samples at 24, 48 and 72 h. The data were presented as means ± s.e.m.
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promoter, suggesting that the radiation-inducible expression vector is as effective as the CMV promoter for radiosensitization of cancer cells, perhaps a preferred system when combined with radiation treatment if the radiation-responding motifs are identified. These data also suggest that the radiation-inducible expression vector may be locally controllable by turning on and off target gene expression, as controls with no radiation show less TNF-a from IEX-driven vector than CMV vector.
Effects of TNF-a on tumor growth in human prostate and cervix tumor xenograft animal models Following initial optimization of experimental conditions in cells and the animal model, we determined TNF-a radiosensitization when produced under the control of these two promoters implanted into cervix (SW756) and prostate (PC3) tumor xenografts. Tumors implanted with one GeneSeed delivering the expression vectors, pCMV-TNF-a or pIEX-1-TNF-a, were treated with sham or g-radiation (2 Gy per day for 10 days). Tumor growth was then monitored over 60-75 days. Mice bearing cervical cancer xenograft tumors exhibited that TNF-a driven by the IEX-1 promoter plus IR treatment significantly decreased the volumes of the initial tumors and showed significantly better inhibition of tumor growth than IR alone (Figure 3a ). Tumors seeded with pIEX-1-TNF-a without irradiation increased in tumor volume. Similar results were obtained from mice bearing prostate cancer xenograft tumors. Implantation of pCMV-TNF-a, IR and pIEX-TNF-a þ IR all showed a significant inhibition of tumor growth compared with the lipofectin control (Figure 3b ). The mean relative tumor volume for the pIEX-TNF-a þ IR treatment was initially significantly lower (Po0.05) than the control at day 14 and remained low until the trial was terminated. TNF-a expressed from the CMV promoter showed the inhibitory effect on tumor growth by gradual reduction up to 50% by 75 days, while Student's t-tests were performed to determine whether the differences between the two treatments were significant. ANOVA testing was performed to determine whether the change in volume during the time course was significant. Po0.05 was considered statistically significant. Data is presented as means ± s.e.m. the tumor growth from the IR treatment alone had begun to re-grow (Figure 3c ). In summary, the rate of tumor growth regression apparently differed between the three treatments: pCMV-TNF-a, IR and pIEX-TNF-a plus IR. pIEX-TNF-a plus IR treatment had a significant larger inhibitory effect on tumor growth than the pCMV-TNF-a or IR alone treatments. In fact, pIEX-TNFa þ IR resulted in decreased tumor volume in all tumors within the sample group (n ¼ 10), with 60% of the tumors disappearing completely by the conclusion of the time course. While none of the tumors in the IR alone treatment group (n ¼ 5) disappeared, 25% of tumors in the pCMV-TNF-a treatment group (n ¼ 8) had a volume of 0 mm 3 at the conclusion of the experiment. pCMV-TNF-a and IR had comparable inhibition of tumor growth; however, the effects of pCMV-TNF-a are longer lasting. The tumor growth in pCMV-TNF-a-treated mice was still inhibited at day 75, while the tumor growth from IR treatments had begun to grow again. The improved response to pCMV-TNF-a compared with IR was not significantly different until day 69.
Feasibility of combining GeneSeed treatments with
Pd-103 in a human prostate tumor xenograft animal model We then tested a feasibility of using radioactive seeds with GeneSeed delivering radiation-inducible TNF-a. Two seeds were simultaneously implanted: a GeneSeed loaded with pIEX-1-TNF-a was implanted in xenograft tumors and a radioactive seed loaded with 100 mCi of Pd-103 was implanted proximate to the tumor. Tumor growth was then monitored over 75 days. The combination of the IEX-1 promoter-driven TNF-a and radiation from the Pd-103 radiation source (seed) significantly suppressed tumor growth as compared with the control irradiation by a Pd-103 source alone and a seed containing lipofectin. Both led to increased tumor volume (Figure 4) . The mean relative tumor volume for the pIEX-TNF-a þ Pd-103 experiment was initially lower (Po0.05) than the control and the Pd-103 seed alone within 10 days and remained low until the trial was terminated. Although tumor growth was slower than growth observed in sham radiation control groups, Pd-103 radiation treatment alone conferred a small delay in tumor growth.
In summary, the rate of tumor growth regression apparently differed comparing the three treatments: pCMV-TNF-a, IR and pIEX-TNF-a plus IR. pIEX-TNF-a plus IR treatment had a significant greater inhibitory effect on tumor growth than the pCMV-TNF-a or IR alone treatments. pIEX-TNF-a þ IR resulted in decreased tumor volume in all tumors within the sample group (n ¼ 10), with 60% of the tumors disappearing completely (volume 0 mm 3 ) by the conclusion of the experimental interval. None of the tumors in the IR alone treatment group (n ¼ 5) disappeared, and 25% of tumors in the pCMV-TNF-a treatment group (n ¼ 8) had a volume of 0 mm 3 at the conclusion of the experiment. pCMV-TNF-a and IR had comparable inhibition of tumor growth; however, the effects of pCMV-TNF-a are longer lasting. The tumor growth in pCMV-TNF-a-treated mice continued to show inhibition at day 75, while tumor growth was observed following IR treatment alone. In addition, the tumor growth inhibition was significantly more effective following co-implantation of Geneseed (pIEX-TNF-a) and Pd-103 than growth observed in Pd-103 radiation alone groups.
Discussion
Gene therapy offers the potential to advance the treatment and potential cure of many diseases that are incurable by conventional methods. To date, many strategies of gene therapy have been explored, including plasmid or recombinant viral vectors carrying therapeutic genes. Current gene therapy approaches for the treatment of cancers include systemic and/or locoregional delivery of vectors. However, the major obstacles associated with gene therapy in humans are poor targeting selectivity of the vectors, inefficient gene transfer and occasionally serious systemic side effects. Therefore, achieving the full potential of gene therapy requires additional improvements in the delivery of therapeutic gene products to tumor cells.
Combination therapies, such as radiation and cytokine (that is TNF-a), have killing effects on cancer cells that Figure 4 Comparison of efficacy of Pd-103 alone and combined treatment with GeneSeed (IEX-driven TNF-a) and Pd-103 in PC3 tumor xenografts. Tumors were implanted with one Pd-103 seed (100 mCi) or with one GeneSeed delivering pIEX-1-TNF-a. The vehicle (lipofectin) only was used for the control group. Tumor growth was then monitored over 75 days. All statistical analysis was performed on the relative tumor volume (percentage change from initial tumor volume) for each tumor. Student's t-tests were performed to determine whether the differences between the two treatments were significantly different. ANOVA testing was performed to determine whether the change in volume during the time course was significant. Po0.05 was considered statistically significant. Data is presented as means±s.e.m.
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Prostate tumor regression by TNF-a M Jung et al are greater than the sum of the individual effects. As targeting methods improve for these combination treatments, one can expect fewer side effects, increased localized doses and higher percentages of favorable patient outcomes. In this report, the feasibility of a novel approach for interstitial delivery of gene therapy by locally expressing TNF-a from a radiation-inducible promoter was tested in human cervix and prostate tumor animal models. This approach improves our ability to control local cervix and prostate tumors because the therapeutic target gene, TNF-a, is expressed only in the tumors and produces a gradient of TNF-a that simultaneously function both as an anti-tumor agent by itself and as a local radiosensitizer, potentially enhancing the therapeutic ratio (by increasing the volume of tumors cells killed by the TNF-a gradient and by reducing the radiation dose needed for any desired amount of tumor cell killing).
Our data support the feasibility of using radiationinducible vectors for radiation sensitization. TNF-a expression via either pCMV-TNF-a or pIEX-1-TNF-a markedly sensitized cells to radiation. The amount of secreted TNF-a was also significantly increased following radiation exposure of cells. Furthermore, pIEX-TNF-a plus IR treatment had a significantly larger inhibitory effect on tumor growth than the pCMV-TNF-a or IR alone treatments. Following implantation with GeneSeed delivering the expression vectors, pCMV-TNF-a or pIEX-1-TNF-a, TNF-a driven by pIEX-1 plus IR treatment decreased the volumes of the initial tumors and showed better inhibition of tumor growth than either IR or TNF-a by CMV alone. These differences were more apparent later in the trial (day 19-75). Furthermore, our approach using co-implantation of seeds plasmids containing with Pd-103 seeds showed feasibility by stabilizing tumor size. These data support the feasibility and rationale for further development of combined treatment with interstitial BRT and GeneSeed TNF-a delivery to improve the current therapy.
In summary, the experimental results confirm that cellular radiation sensitivity is increased by TNF-a expression from either constitutively expressed by the CMV promoter or only after radiation for the IEX promoter, suggesting that the radiation-inducible expression vector is as effective as the CMV promoter for radiosensitization of cancer cells. Furthermore, this may prove to be a preferred system when combined with radiation treatment if the radiation-responding motifs are identified. These data also suggest that the radiationinducible expression vector may be specially controllable by turning target gene expression on and off, as supported by the data showing that expressed levels of TNF-a from the IEX-1 promoter-driven vector were much less (similar to the control with mock transfection) than levels following irradiation. Furthermore, the combination of radiation and cytokines produced locally from a radiation-inducible promoter is superior to irradiation alone or locally produced cytokine alone. Therefore, the result supports this innovative approach with clinically relevant radiation doses. The ability to co-deliver radiationsensitizing genes or cytokines along with radiation seeds using interstitial placement techniques that radiation oncologists already use may gain acceptance for use in combination therapy of locally advanced tumors. Furthermore, GeneSeeds should enable efficient local, targeted delivery of gene therapy viruses to tumors.
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